Indication: Head and Neck Cancer
Phase II, Open-Label, Multi-Center Study of PDS0101 (ImmunoMAPK-RDOTAP/HPV-16 E6 & E7 peptides) and Pembrolizumab (KEYTRUDA) Combination Immunotherapy as a First Line Treatment in Subjects with Recurrent and/or Metastatic Head and Neck Cancer (HNSCC) and High-risk Human Papillomavirus-16 (HPV16) Infection
Sub-indication: Head and Neck Cancer
Study Type: Drug Study
Principal Investigator: Jaspreet Grewal, M.D.Norton Cancer Institute
Sponsor: Sponsor: PDS Biotechnology Corporation
Learn more at ClinicalTrials.gov
Email for more information: Head&Neck-NCIResearch@nortonhealthcare.org